anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SIGNIFICANCE: Autonomous vehicles (AVs) have the promise to be an alternative transportation solution for those with vision loss. However, the impact of vision loss on the perceptions and concerns of AVs is unknown. This study therefore examined whether AVs are perceived differently by blind, visually impaired (VI), and normally sighted people.
PURPOSE: This study compared the perceptions of AVs among the blind, VI, and normally sighted.
METHODS: Participants' opinions on four perception measures (general opinion, trust, impact on quality of life, and intention to use AVs) and nine concerns regarding AVs were measured. The survey was administered to 51 normally sighted, 68 VI, and 65 blind participants. Analyses of covariance assessed whether the four perception measures and nine concerns varied by vision status (normal vision, VI, blind) and driving status (driver, nondriver). Univariate correlations and multiple regression analyses identified associations and predictors of AV perceptions and concerns from demographic, mood, cognition, travel behavior, and vision measures, which included visual acuity, contrast sensitivity, and visual field.
RESULTS: The blind (p<0.001), VI (p<0.001), and nondrivers (p<0.001) showed a greater intention to use AVs compared with those with normal vision and drivers. Similar findings were found for the other perception measures. As visual acuity, contrast sensitivity, and visual field extent declined, positivity toward AVs increased (p<0.001). Visual field extent best predicted general opinion and trust in AVs, whereas driving measures were the best predictors of impact on quality of life and intention to use AVs. Concerns about AVs showed no differences based on vision (p=0.94) or driving (p=0.63) status.
CONCLUSIONS: Individuals with vision loss expressed more acceptance of AVs despite their concerns. How positive someone is toward AVs appears to be dependent on their visual field extent and driving status.
Percutaneous coronary intervention (PCI) and related interventional cardiology field are rapidly growing in current era. First generation drug eluting stent (DES) needed long-term dual antiplatelet therapy (DAPT) for preventing future stent thrombosis. But, second generation DES showed better clinical outcomes in terms of target lesion revascularization and stent thrombosis. Later, polymer technology that was used to release drugs gradually improved. BASKET-PROVE II trial compared biodegradable polymer (BP) DES (Nobori, Terumo) with durable polymer DES (Xience Prime, Abbott Vascular) and bare metal stent (ProKinetik, Biotronik) for the safety and efficacy in 2-year follow-up. BP-DES showed 7.6% of event rates in composite endpoint including cardiac death, myocardial infarction (MI), clinically indicated target-vessel revascularization (TVR) which was non-inferior to DP-DES(6.8%) and superior to bare metal stent (12.7%). There were no statistical differences for the event rates of stent thrombosis, MI and cardiac death among three groups in 1-year follow-up. Biodegradable polymer has begun to emerge and suggested the possibility of shortening the duration of DAPT. LEEDERS-FREE trial was designed to confirm the safety and efficacy of polymer-free drug-coated stent (Biofreedom, Biosensors International Technologies, Singapore) compared to bare metal stent (Gazelle stent, Biosensors International Technologies, Singapore) in patients with high bleeding risk. During 390 days, drug coated stent showed significant superiority to bare metal stent for the safety composite endpoint (cardiac death, MI or stent thrombosis) (9.4% vs. 12.9%, P=0.0005). Clinically-driven target-lesion revascularization also showed significant differences between drug-coated stent (5.1%) and bare metal stent (9.8%) (P\<0.001). This results provided new therapeutic options that DAPT duration could be shortened to 1 month in patients with high bleeding risk. The rate of cardiovascular events was relatively higher than second generation DES. However, this result should be carefully interpreted because the main purpose of LEADERS-FREE trial is to enroll high bleeding risk patients who are generally excluded in second generation DES studies. Additional studies are needed because there are limited clinical evidences for extending these findings of LEADERS-FREE trial to generalized patients who are eligible to PCI.
The intervention group will receive anti-epileptic drug treatment according to the guideline of American Epilepsy Society 15 for 12 weeks. The recommended regimens include zonisamide, lamotrigine, or levetiracetam at the minimal therapeutic doses (zonisamide 100mg twice daily, levetiracetam 500mg twice daily, lamotrigine 50mg twice daily), and the choices depend on tolerability of the participants and contraindications (allergy to any drugs, or allergy to sulphonamides in zonisamide users). The participants will be followed every 4 weeks.
Adult participants with end-stage renal disease (ESRD) (eGFR \<15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
FIELD: hygiene.SUBSTANCE: group of inventions relates to oral care. Oral care composition contains a carrier acceptable for use in the oral cavity and 2.5 wt. % of zinc lactate dihydrate composition; 0.454 wt. % of stannous fluoride composition; 3 wt. % of sodium tripolyphosphate composition; 2 % by weight of composition of sodium tetrapyrophosphate; buffer system. Also disclosed is a method of treating or reducing intensity of erosion of dental enamel, plaque and caries.EFFECT: group of inventions provides protection against loss of mineral substances and inhibition of bacterial growth.9 cl, 4 tbl, 3 ex
The present invention involves diagnostic and treatment methods for prostate cancer. We have shown that prostate cancer cells overexpress variant isoforms of CD44 (CD44v7-10). Overexpression is observed at the messenger RNA and protein levels. The present invention includes using diagnostic procedures such as RT-PCR and in situ hybridization to distinguish prostate cancer cells from benign prostate tissue. In addition, the present invention involves RNA interference (RNAi) targeted to a region of CD44v7-10 and to Muc18 as a treatment method for PC. We have shown that RNAi targeted to CD44v7-10 and to Muc 18 decreased invasiveness of two PC cell lines. Therapeutic methods of the present invention include gene therapy with RNAi, antisense, or ribozymes targeted against CD44v7- 10 or Muc 18 in cancer cells in vivo.
Using alpha 1-antichymotrypsin (ACT) polypeptide, its functional variant and/or encoding nucleic acid, or of a cell expressing ACT polypeptide or its encoding nucleic acid, in combination with alpha 1-antitrypsin (AAT) polypeptide, its functional variant or encoding nucleic acid, or with a cell expressing AAT polypeptide or its encoding nucleic acid, for treating and/or preventing poorly healing diabetes-associated and/or arterial wounds, is new. An independent claim is also included for a method of manufacturing a pharmaceutical composition for treating and/or preventing the diseases described above where the ACT polypeptide or its encoding nucleic acid or a cell expressing the ACT polypeptide or its encoding nucleic acid is combined with the AAT polypeptide or its encoding nucleic acid or a cell expressing the AAT polypeptide or its encoding nucleic acid. ACTIVITY : Vulnerary; Antiulcer; Antidiabetic. Diabetes was induced in male Sprague Dawley rats of 250-300 g body weight by injecting intraperitoneally with streptozotocin. The backs of the 4 diabetic and 4 nondiabetic control animals were depilated and 4 sites were marked for subsequent wounding. Plasmid DNA (0.5 Microg) was shot into each site with in each case 2 sites being bombarded with the ACT expression vector pMHIntACT and 2 sites being bombarded with the control vector pMHIntLuc. The tensile strength of the wounds treated with pMHIntACT was clearly increased in the diabetic animals. Administration of the plasmid had no significant effect in the control animals. MECHANISM OF ACTION : Gene therapy; Protein therapy.
A computer-implemented method and a computer system are disclosed. The computer system (200, 300) is suitable for detecting an operating state of a blood treatment machine (100, 201, 202, 20 . . . , 20n) or of a course of treatment in a blood treatment or a deviation from an ideal or uncomplicated operating state or a course of treatment. The computer system comprises a first interface (20, 312), which is adjusted to receive an operating parameter monitoring signal, wherein the operating parameter monitoring signal represents a time-dependent signal of a sensor for monitoring an operating parameter of the blood treatment machine or a signal derived from the time-dependent signal of the operating parameter, anda second interface (20, 312), which is adjusted to receive a user response signal, wherein a user response signal represents a signal of a user input with respect to the operating state or the course of treatment or the deviation from the ideal or uncomplicated course of treatment or operating state of a blood treatment performed using the blood treatment machine. The computer system additionally comprises an evaluation unit (40, 213), which is adjusted to generate allocation data or reference data, establishing a correlation between a determined user response and a respective operating parameter monitoring signal, a memory unit, which is configured to save the allocation data and reference data, wherein the evaluation unit is also adjusted to compare a determined operating parameter monitoring signal with the allocation data or reference data to derive from this an operating state, a course of treatment or a deviation from an ideal or uncomplicated operating state or course of treatment of the blood treatment machine or a typical user response thereto.
The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non­fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development.
Sotalol hydrochloride USP is an antiarrhythmic drug with Class II (beta-adrenoreceptor blocking) and Class III (cardiac action potential duration prolongation) properties. It is supplied as a light-blue, capsule-shaped tablet for oral administration. Sotalol hydrochloride USP is a white, crystalline solid with a molecular weight of 308.8. It is hydrophilic, soluble in water, propylene glycol and ethanol, but is only slightly soluble in chloroform. Chemically, sotalol hydrochloride USP is d,l-N-[4-[1-hydroxy-2-[(1-methylethyl) amino]ethyl]phenyl]methane-sulfonamide monohydrochloride. The molecular formula is C12H20N2O3S•HCl and is represented by the following structural formula:

Each sotalol hydrochloride tablet USP, for oral administration, contains 80 mg, 120 mg, 160 mg or 240 mg of sotalol hydrochloride. Each tablet also contains the following inactive ingredients: colloidal silicon dioxide, FD&C blue No. 1 aluminum lake, hydroxypropyl cellulose, lactose anhydrous, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.
Process for encapsulating active principle particles by spraying a silicon thermoplastic copolymer in solution in an organic solvent or in dispersion or in aqueous emulsion and eliminating, by hot-air drying, the solvent or the water. The process for spraying/drying used is, for example, the Wurster method. The copolymer that can be used is formed by a sequence of segments or polydiorgano-siloxane blocks and segments or organic blocks including polyesters, polyethers, polyurethanes and polystyrenes. It can also be a polydiorganosiloxane grafted by organic chains. The active principle is in the form of size-graded particles comprised between 50 νm and 5 mm. The active principle can be a catalyst, a perfume, a colouring agent, a cosmetic product, a drug, a phytosanitary product, vegetable seeds and the like. Application: in particular, for the controlled liberation of an active principle in an aqueous medium.
FIELD: pharmacology. ^ SUBSTANCE: claimed invention relates to novel application of lignan compounds represented by formula I, given in description. In particular claimed invention relates to pharmaceutical composition for treatment or prevention of brain disease, which contains lignan compound, represented by formula I or Myristica fragrans extract as active ingredient, as well as method and application for treatment or prevention of brain disease with application of lignan compound. Lignan compound represented by formula I possesses anti-oxidative, protective for brain cells and anti-inflammatory effect. ^ EFFECT: lignan compound will be useful for treatment or prevention of brain diseases. ^ 14 cl, 16 dwg, 2 tbl
The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
PURPOSE:If crystallized glass is used as restoration, the color tone of an abutment tooth is reflected by its transparency and an aesthetic property is inferior and, therefore, there is a need for concealing the color of the abutment tooth in the case a metallic material, such as silver alloy, is used for the abutment tooth at the time of restoring the dental crown. CONSTITUTION:The dental crown restoration 4 consisting of the crystallized glass 2 is constituted by joining an opaque layer of a ceramic or resin type to the inside surface of the restoration 4. More particularly, the crystallized glass 2 is the crystallized glass of a calcium phosphate system and the opaque layer is the ceramic type and is preferably formed by kneading a powder mixture composed of 30 to 90 pts.wt. phosphate glass powder, 10 to 70 pts.wt. refractory inorg. powder having a hiding property, <=70 pts.wt. inorg. coloring pigment powder, and <=10 pts.wt. oxidizing material with a kneading liquid, then applying and calcining the mixture.
This systematic review investigates Patient-reported Outcome Measures (PROMs) and Observed Reported Outcome Measures (ObsROMs) pertinent to assessing Health-Related Quality of Life (HRQoL) in short-stature paediatric patients, focusing on Achondroplasia (ACH), Growth Hormone Deficiency (GHD), Isolated Growth Hormone Deficiency (IGHD), and Small-for-Gestational-Age (SGA) diagnoses. Utilising rigorous selection criteria, 53 studies published from 1998 to 2023 were analysed, revealing a predominance of European-based research. Notably, the review elucidated the utilisation of disease-specific and generic HRQoL measures, showcasing the multifaceted nature of short-stature conditions and their impact across physical, emotional, and social domains. The Quality of Life in Short Stature Youth (QoLISSY), Paediatric Quality of Life Inventory (PedsQL), and KIDSCREEN emerged as frequently employed instruments, offering nuanced insights into HRQoL perceptions across diverse age demographics. Additionally, the review highlighted the adaptation of adult HRQoL measures for adolescent populations, signalling a need for age-appropriate assessment tools. Furthermore, integrating PROMs and ObsROMs in HRQoL assessment underscored a comprehensive approach, considering both subjective patient perspectives and observed outcomes. Future research directions encompass comprehensive search strategies, longitudinal studies with diverse populations, and the development of age-appropriate HRQoL assessment tools. In conclusion, this review emphasises the importance of comprehensive HRQoL assessment to address the diverse needs of short-stature paediatric patients effectively.
Uric acid nephropathy (UAN), caused by a common metabolic disorder resulting from hyperuricemia (HUA), has an increasing incidence. Previous studies have shown that berberine (BBR) has clear urate-lowering and anti-inflammatory effects in UAN mice, but its mechanism needs to be further clarified. Therefore, Potassium Oxonate (PO) combined with hypoxanthine (HX) induced UAN mice model and MSU induced THP-1 cells polarization model were adopted to investigate the mechanism of BBR on UAN in terms of tissue distribution and molecular pharmacology. Study unveiled that BBR was first found to bind to red blood cells (RBCs), which were recognized and phagocytosed by monocytes, then recruited by the injured kidney. Subsequently, BBR was enriched and functional in damaged kidney. The results of in vivo experiments revealed that, BBR reduced UA, BUN, CRE levels as well as the release of TNF-α, IL-1β, IL-18 and IL-6, and alleviated renal injury in UAN mice, as consistent with previous studies. Additionally, BBR decreased MCP-1 expression, while diminishing macrophage infiltration and decreasing M1 proportion as determined by RT-qPCR. In vitro experiments, demonstrated that MSU promoted inflammatory polarization of THP-1 cells, while BBR reduced synthesis of inflammatory factors and inhibited MSU-induced inflammatory polarization. These effects of BBR were dependent on AMPK activation along with indirect inhibition of NF-κB signaling pathway mediated. However, the anti-inflammatory and macrophage polarization regulation effects of BBR were completely reversed upon administration of Compound C, an AMPK inhibitor. Therefore, BBR ameliorated kidney injury via regulating macrophage polarization through AMPK, which has therapeutic potential for UAN patients.
The invention discloses application of dragon blood leaves. The application of the dragon blood leaves is application of the dragon blood leaves in preparation of a medicine or a medical instrument for treating mammary gland hyperplasia. The medical instrument is a bra for treating the mammary gland hyperplasia. The bra for treating the mammary gland hyperplasia is obtained by the following steps of separately packaging dragon blood leaf powder into semicircular gauze medicine bags, selecting a bra appropriate for a mammary gland hyperplasia patient, and inserting the medicine bags into bra interlayers corresponding to diseased regions to obtain the bra for treating mammary gland hyperplasia. A series of tests show that the dragon blood leaves can treat the mammary gland hyperplasia. By a unique preparation process, the effect of treating the mammary gland hyperplasia is better enhanced; and a firm foundation is laid for treatment of the mammary gland hyperplasia.
This is a single center, single-arm, open-label trial. Approximately 30 evaluable ears will be enrolled that have at least 50% cerumen impaction. All ears/subjects will receive at least a single dose (approximately 1 - 2 mL) of the test product applied topically in the study ear canal. The test product will be supplied from a qualified compounding pharmacy that receives a by-subject prescription from the investigator. The subject will be dosed with the head tilted in order to keep the test product in the ear canal for 15 minutes. At 5 and 10 minutes, subjects will be instructed to move their jaw up and down (and side to side) a few times and, manipulate/massage the ear canal by pressing between jawbone and ear lobe with a rotating motion for 10 seconds, which may aid in distribution of the test product in the ear canal. Fifteen minutes after product instillation, it will be removed by having the subject tilt the head over a disposable container to catch the solution. The ear canal will be irrigated (low pressure) with warm water and, the evaluator will try to visualize the tympanic membrane using an otoscope (before and after lavage). The amount (change in area, volume and depth) of the tympanic membrane that can be visualized and the categorization of cerumen impaction (according to a 5 point scale) is the primary efficacy parameter of this study. Efficacy will also be assessed using subjective questions (improvement and change in symptoms) that will be asked by the study staff and documented prior to the subject having any knowledge of the otoscope results (visualization of TP).
This invention is the preparation method of carboxymethyl chitosan calcium. The procedure is as followings: dissolve carboxymethyl chitosan calcium in water, react with the aqueous solution or powder of one among calcium chloride, calcium acetate, calcium gluconate and calcium lactate, filer, centrifuge, wash the solid product, dessicate and dry. The carboxymethyl chitosan calcium's molecular weight is in the range of 1KD-1000KD. Weitht ratio in the reaction between carboxymethyl chitosan calcium and chitosan calcium (the others is the same) is 10:0.1-6. The carboxymethyl chitosan calcium we get here could be used wound or operational haemostasis. It also helps supplement calcium and get rid of the deleterious element lead. In the conclusion, our product carboxymethyl chitosan calcium could be used as haemostatic, replenishing calcium regent and anti-lead reagent.
The TIL product will be produced from excised tumor lesions from the patient. Expanded TILs will be transferred to the patient after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose IL-2 and nivolumab anti-PD-1 treatment. The transplant product will be produced in the Good Manufacturing Practice (GMP) facility of the University Hospital in Basel. TIL transfer to Patient at Day 0.
Use of a peptide of formula (I) (given below) as an antioxidant and/or anti-free radical agent, optionally in combination with another active agent, for preparation of a cosmetic and/or a dermatological composition, is new. Use of a peptide of formula (I) as an anti-oxidant and/or an anti-free radical agent, optionally in combination with another active agent, for the preparation of a cosmetic and/or dermatological composition, is new. An independent claim is also included for a dermatological composition (II) comprising a cosmetically or pharmaceutically acceptable medium and a peptide of formula (I). ((Xaa)n-Cys-Gly-(Xaa)n, (I), where Xaa represents any amino acid or amino acid derivative, and n is 0-2. ACTIVITY : Dermatological. The ability of (II) to prevent the cellular damage by ultraviolet radiation was tested using biological assays. The results showed that (II) increased the viability of the cells to 14.5% compared to the untreated cells. MECHANISM OF ACTION : Antioxidant; Free radical scavenger.